

GSK on track to deliver 2024 outlooks with further good progress made in R&D

“We have delivered another quarter of sales and core operating profit growth, and further good progress in R&D. Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have now built into GSK’s portfolio and performance. Our pipeline continues to strengthen with 11 positive phase III trials reported so far this year and we are currently planning launches for 5 major new product approval opportunities next year: *Blenrep*, *Depemokimab*, *Nucala* for COPD, *Gepotidacin*, and our new vaccine to prevent meningitis (*MenABCWY*). We also resolved the vast majority of *Zantac* litigation in the quarter, to remove uncertainty and so we can focus forward. All this means we are on track to deliver our 2024 guidance, and we are even more confident in our 2026 and 2031 outlooks.”

Emma Walmsley
Chief Executive Officer, GSK



Specialty Medicines
£3.0bn +19%
HIV +12%, Oncology +94%
Respiratory/Immunology and other +14%

Vaccines
£2.7bn -15%

General Medicines
£2.4bn +7%

Core operating profit	Total EPS*	Core EPS	Dividend
£2.8bn +5%	-1.4p -100%	49.7p +5%	15p

Total sales year to date +9% (ex COVID)	Core operating profit year to date +19% (ex COVID)	11 positive data readouts on phase III trials so far this year	5 major new product approval opportunities next year
--	---	--	--

Journalists, media and investors see press release on www.gsk.com for full details on Q3 2024.
Please read the cautionary statement regarding forward-looking statements on page 54 and the definitions and reconciliations for non-IFRS measures on pages 18, 20-21, 23-24 and 52 of the press release.
Product group sales may not add to total sales due to rounding.
References to growth are at constant exchange rates (CER) unless stated otherwise.
*Total EPS driven by a charge of £1.8 billion (\$2.3 billion) in relation to the *Zantac* settlement.